US regulators are willing to reconsider using a Phase 3 study of tab-cel as the basis for an approval, after previously rejecting the therapy based on that same study.
There’s new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals.
US regulators are willing to reconsider using a Phase …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA to reconsider treatment for rare cancer after its surprise rejection
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
FDA revisits a rare cancer treatment it rejected a few months ago
Astellas treatment offers new hope to a devastated rare disease community
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
Avalo shares spike on skin drug data; BioNTech to cut staff
Five years after disaster, a rare disease community gets new chance at treatment
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
